G
o
o
g
l
e
×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Shopping
Maps
Videos
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration ...
CureVac
CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on...
2 months ago
German court quashes CureVac patent after challenge by BioNTech
Reuters
A German court on Tuesday invalidated a patent that was the basis of a patent violation lawsuit brought by CureVac against its domestic...
3 months ago
CureVac races for 100 million COVID-19 vaccine doses by end of 2020
Yahoo Movies UK
Dietmar Hopp, the billionaire majority shareholder in CureVac (CVAC) said that the German biotech will likely not be first in the global...
1 day ago
CureVac touts COVID-19 vax data despite adverse events
Fierce Biotech
CureVac's COVID-19 vaccine candidates produced meaningful immune responses—though grade 3 adverse events were recorded in the mid-stage...
2 months ago
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Simply Wall St
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
1 week ago
CureVac (NASDAQ:CVAC) Shares Gap Up to $2.94
MarketBeat
CureVac (NASDAQ:CVAC - Get Free Report)'s stock price gapped up before the market opened on Wednesday . The stock had previously closed at...
19 hours ago
CureVac announces positive Phase II Covid-19 vaccine trial data
Clinical Trials Arena
The CureVac and GSK Covid-19 collaboration was first announced in February 2021, with regulatory discussions already in motion for next...
2 months ago
CureVac: No Momentum In Sight (NASDAQ:CVAC)
Seeking Alpha
CureVac's mRNA future is uncertain, as a German court invalidates a key patent, raising concerns about their ability to compete.
3 weeks ago
CureVac stock gains as COVID vaccine candidates show promise
MarketWatch
CureVac N.V. shares gained 3% premarket on Friday as the company released new data from a trial of its mRNA COVID-19 vaccine candidates,...
2 months ago
CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE
CureVac
CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on...
3 months ago